Cobicistat: A review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection

Drugs

Volumn 74, Issue 2, 2014, Pages 195-206

  Deeks, Emma D ^a  

^a NONE   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; AMIODARONE; ATAZANAVIR; CARBAMAZEPINE; CISAPRIDE; COBICISTAT; CREATININE; DARUNAVIR; DIHYDROERGOTAMINE; ELVITEGRAVIR; ERGOMETRINE; ERGOTAMINE; MEVINOLIN; MIDAZOLAM; PHENOBARBITAL; PHENYTOIN; PIMOZIDE; PLACEBO; PROTEINASE INHIBITOR; QUINIDINE; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SILDENAFIL; SIMVASTATIN; TELAPREVIR; TERFENADINE; TESTOSTERONE; TRIAZOLAM; UNINDEXED DRUG; CARBAMIC ACID DERIVATIVE; CYP3A PROTEIN, HUMAN; CYTOCHROME P450 3A; CYTOCHROME P450 3A INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; OLIGOPEPTIDE; PYRIDINE DERIVATIVE; SULFONAMIDE; THIAZOLE DERIVATIVE;

ADIPOCYTE; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERBILIRUBINEMIA; IC 50; JAUNDICE; KIDNEY FUNCTION; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; LIPID METABOLISM; MAXIMUM PLASMA CONCENTRATION; MODERATE RENAL IMPAIRMENT; NAUSEA; PATIENT PARTICIPATION; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SCLERA DISEASE; SEVERE RENAL IMPAIRMENT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VIROLOGY; DRUG EFFECTS; HIV INFECTIONS; METABOLISM;

CARBAMATES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 CYP3A INHIBITORS; DRUG SYNERGISM; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; OLIGOPEPTIDES; PYRIDINES; SULFONAMIDES; THIAZOLES;

EID: 84895730451     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0160-x     Document Type: Article

References (45)

1. Williams I, Churchill D, Anderson J, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med. 2012;13 Suppl 2:1-85. Plus update available at http://www.bhiva.org/documents/Conferences/Autumn2013/presentations/131114/ DuncanChurchill.pdf. Accessed 26 Nov 2013.
2. European AIDS Clinical Society. Guidelines version 7.0, October 2013. 2013. http://www.eacsociety.org/Portals/0/Guidelines-Online-131014.pdf. Accessed 19 Nov 2013.
3. Arts EJ, Hazuda DJ. HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med. 2012;2(4):a007161.
4. Gras J. Cobicistat. Cytochrome P450 CYP3A inhibitor, anti-HIV agent. Drugs Future. 2012;37(5):315-24.
5. Arya V, Robertson SM, Struble KA, et al. Scientific considerations for pharmacoenhancers in antiretroviral therapy. J Clin Pharmacol. 2012;52(8):1128-33.
6. Kuritzkes DR. Drug resistance in HIV-1. Curr Opin Virol. 2011;1(6):582-9.
7. Josephson F. Drug-drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition. J Intern Med. 2010;268(6):530-9.
8. Shah BM, Schafer JJ, Priano J, et al. Cobicistat: a new boost for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2013. doi: 10.1002/phar.1237.
9. Breitenbach J. Melt extrusion can bring new benefits to HIV therapy. Am J Drug Deliv. 2006;4(2):61-4.
10. Mascolini M. What will it take to replace ritonavir as the prime PK booster? Debate ritonavir v GS9350 [conference report]. 11th International Workshop on Clinical Pharmacology of HIV Therapy; 7-9 Apr 2010; Sorrento.
11. Gilead Sciences International Ltd. Tybost 150 mg film-coated tablets: EU summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/002572/WC500153014.pdf. Accessed 19 Nov 2013.
12. Gilead. Gilead's boosting agent cobicistat for HIV therapy as effective as ritonavir in pivotal phase 3 study [media release]. 24 Jul 2012. http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle- pf&id=1717796.
13. Gilead Sciences Inc. Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) tablets, for oral use: US prescribing information. 2013. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/ 203100s009lbl.pdf. Accessed 19 Nov 2013.
14. Gilead Sciences International Ltd. Stribild 150 mg/150 mg/200 mg/245 mg film-coated tablets: EU summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/002574/WC500144272.pdf. Accessed 19 Nov 2013.
15. Perry CM. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild): a review of its use in the management of HIV-1 infection in adults. Drugs. 2013. doi: 10.1007/s40265-013-0158-4.
16. Callebaut C, Tsai L, Stray K, et al. Biological profiling of GS-9350, a novel pharmacoenhancer that lacks anti-HIV activity and exhibits low potential for metabolic adverse effects in vitro [abstract]. Antivir Res. 2010;86(1):A31.
17. Lepist EI, Murray BP, Tong L, et al. Effect of cobicistat and ritonavir on proximal renal tubular cell uptake and efflux transporters [abstract no. A1-1724 plus poster]. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 17-20 Sept 2011; Chicago (IL).
18. Post F, Andrade-Villanueva J, Fisher M, et al. Renal safety of elvitegravir/cobicistat/emtricitabine/tenofovir DF (STB) and cobicistat-boosted protease inhibitor regimens in HIV-1-infected patients with mild to moderate renal impairment [abstract no. TUPE280 plus poster]. 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 30 June-3 July 2013; Kuala Lumpur.
19. Ramanathan S, Warren D, Wei L, et al. Pharmacokinetic boosting of atazanavir with the pharmacoenhancer GS-9350 versus ritonavir [poster A1-1301]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 12-15 Sep 2009; San Francisco (CA).
20. German P, Wei X, Mizuno V, et al. Pharmacokinetics of elvitegravir and cobicistat in subjects with severe renal impairment [abstract no. P-38]. 13th International Workshop on Clinical Pharmacology of HIV Therapy; 16-18 April 2012; Barcelona.
21. Xu L, Liu H, Murray BP, et al. Cobicistat (GS-9350): a potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer. ACS Med Chem Lett. 2010;1(5):209-13.
22. Mathias AA, German P, Murray BP, et al. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther. 2010;87(3):322-9.
23. Elion R, Cohen C, Gathe J, et al. Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection. AIDS. 2011;25(15):1881-6.
24. Gallant JE, Koenig E, Andrade-Villanueva J, et al. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results. J Infect Dis. 2013;208(1):32-9.
25. German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. JAIDS. 2012;61(1):32-40.
26. Custodio JM, Gordi T, Jin F, et al. A large population pharmacokinetic evaluation of the influence of demographic and HIV disease factors on the pharmacokinetics of elvitegravir, cobicistat and tenofovir [abstract no. MOPE036]. 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 30 June-3 July 2013; Kuala Lumpur.
27. Mathias A, Liu HC, Warren D, et al. Relative bioavailability and pharmacokinetics of darunavir when boosted with the pharmacoenhancer GS-9350 versus ritonavir [abstract no. 28]. 11th International Workshop on Clinical Pharmacology of HIV Therapy; 7-9 Apr 2010; Sorrento.
28. Kakuda TN, van de Casteele T, Petrovic R, et al. Bioequivalence of darunavir (800mg) co-administered with cobicistat (150mg) as either a fixed-dose combination tablet or as single agents under fasted and fed conditions in healthy volunteers [abstract no. MOPE029 plus poster]. 7th International AIDS Society Conference on HIV Pathogenesis and Treatment; 30 June-3 July 2013; Kuala Lumpur.
29. German P, Mathias A, Wei L, et al. The effect of cobicistat on cytochrome P450 2D6, 2B6 and p-glycoprotein using phenotypic probes [slide presentation]. 12th International Workshop on Clinical Pharmacology of HIV Therapy; 13-15 Apr 2011; Miami (FL).
30. Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev. 2002;23(5):687-702.
31. Lepist E-I, Phan TK, Roy A, et al. Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro. Antimicrob Agents Chemother. 2012;56(10):5409-13.
32. Stray KM, Bam RA, Birkus G, et al. Evaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovir. Antimicrob Agents Chemother. 2013. doi: 10.1128/AAC.00712-13.
33. Ramanathan S, Mathias A, Wei X, et al. Pharmacokinetics of once-daily boosted elvitegravir when administered in combination with acid-reducing agents. JAIDS. 2013;64(1):45-50.
34. Bruce RD, Winkle P, Custodio JM, et al. The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment. J Acquir Immune Defic Syndr. 2013;63(4):480-4.
35. Gilead Sciences. Phase 3, randomized, double-blind study to evaluate the safety and efficacy of GS-9350-boosted atazanavir versus ritonavir-boosted atazanavir each administered with emtricitabine/tenofovir disoproxil fumarate in HIV-1 infected antiretroviral treatment-naive adults [ClinicalTrials.gov identifier NCT01108510]. US National Institutes of Health, ClinicalTrials.gov. 2012. http://www.clinicaltrials.gov. Accessed 19 Nov 2013.
36. Croom KF, Dhillon S, Keam SJ. Atazanavir: a review of its use in the management of HIV-1 infection. Drugs. 2009;69(8):1107-40.
37. Gilead Sciences International Ltd. Viread: EU summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/000419/WC500051737.pdf. Accessed 19 Nov 2013.
38. Cahn P, Sued O. Boosting HIV treatment options: good news, new challenges. J Infect Dis. 2013;208(1):4-6.
39. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2013. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed 19 Nov 2013. Plus update available from http://aidsinfo.nih.gov/news/ 1392/hhs-panel-on-antiretroviral-guidelines-for-adults-and-adolescents-updates- recommendations-on-preferred-insti-based-regimens-for-art-naive-individuals. Accessed 26 Nov 2013.
40. Gilead Sciences. Phase 3b open-label, single arm study to evaluate the safety and efficacy of cobicistat-boosted darunavir in HIV infected adults [ClinicalTrials.gov identifier NCT01440569]. US National Institutes of Health, ClinicalTrials.gov. 2011. http://www.clinicaltrials.gov. Accessed 19 Nov 2013.
41. Coffey S. Cobicistat as a booster of atazanavir. 2012. http://hivinsite.ucsf.edu/InSite?page=hmq-1210-02. Accessed 7 Nov 2013.
42. Stone VE, Jordan J, Tolson J, et al. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr. 2004;36(3):808-16.
43. Molina JM. Efficacy and safety of once-daily regimens in the treatment of HIV infection. Drugs. 2008;68(5):567-78.
44. Kaya S. HIV treatment with once-daily single tablet regimens. J Virol Antivir Res. 2013. doi: 10.4172/2324-8955.1000105.
45. Kakuda TN, Opsomer M, Trimmers M, et al. Bioavailability of two FDC formulations of darunavir/cobicistat 800/150mg compared with darunavir/ritonavir 800/100mg co-administered as single agent [abstract no. 0-20 plus slide presentation]. 13th International Workshop on Clinical Pharmacology of HIV Therapy; 16-18 Apr 2012; Barcelona.